ReviewCureus2025
Intravenous Iron Therapy in Patients Admitted With Acute Heart Failure and Iron Deficiency: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ferric Carboxymaltose Among Patients with Heart Failure and Iron Deficiency: An Updated Meta-Analysis of Randomized Controlled Trials.Cardiovascular toxicology · 2026Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of intravenous (IV) iron in chronic heart failure (HF) has been well studied, becoming a class IA recommendation. However, its role in acute heart failure (AHF) is less well-known. Multiple studies, including randomized controlled trials (RCTs), have been published; however, their clinical benefit remains controversial. We aim to provide enough evidence to support decision-making in this clinical scenario. We performed a systematic review and meta-analysis of IV iron in patients admitted with AHF and iron deficiency (ID). PubMed, Embase, Scopus, and Cochrane databases were searched for trials published up to July 1, 2024. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were pooled across trials. Outcomes included HF and all-cause re-hospitalization, all-cause mortality, and mean change in hemoglobin levels. Of the 362 database results, three RCTs, six observational studies, and 3,588 patients were included. In total, 1,622 (45.2%) patients received IV iron. Re-hospitalization for HF (RR = 0.96; 95% CI = 0.76-1.21; p = 0.74; I² = 74%) showed a downward trend, but this was not statistically significant. Neither was all-cause rehospitalization (RR = 1.03; 95% CI = 0.90-1.19; p = 0.64; I² = 3%) nor all-cause mortality (RR = 1.00; 95% CI = 0.81-1.24; p = 0.87; I² = 0%). A statistically significant mean change in the hemoglobin levels (MD = 0.80; 95% CI = 0.33-1.27; p = 0.0003; I² = 88%) was documented between both groups. In patients with AHF and ID, treatment with IV iron improves hemoglobin levels. Yet, this improvement does not appear to have a significant impact on rehospitalization or all-cause mortality rates. Larger RCTs are needed to further study its effect on clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.